Long-term monitoring of visceral leishmaniasis in patients with AIDS - Relapse risk factors, value of polymerase chain reaction, and potential impact on secondary prophylaxis

被引:47
作者
Bourgeois, Nathalie [1 ]
Lachaud, Laurence [1 ]
Reynes, Jacques [2 ]
Rouanet, Isabelle [3 ]
Mahamat, Aba [4 ]
Bastien, Patrick [1 ]
机构
[1] Ctr Hosp Univ, Ctr Natl Reference Leishmania, Lab Parasitol Mycol, F-34090 Montpellier, France
[2] Ctr Hosp Univ, Serv Malad Infect & Trop, F-34090 Montpellier, France
[3] Grp Hosp Univ, Serv Malad Infect & Trop, Nimes, France
[4] Grp Hosp Univ Caremeau, Lab Parasitol Mycol, Nimes, France
关键词
AIDS; amphotericin B; polymerase chain reaction; relapses; secondary prophylaxis; visceral leishmaniasis;
D O I
10.1097/QAI.0b013e318166af5d
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Molecular methods have become essential in the diagnosis of visceral leishmaniasis (VL) in patients who have AIDS. The present study aimed at (1) identifying relapse risk factors for VL and (2) assessing the value of long-range routine polymerase chain reaction (PCR) monitoring in such patients, (3) with a view to proposing decision-making elements for discontinuing specific secondary prophylaxis. Methods: A cohort of 27 HIV-positive patients was prospectively followed up during a period of 5 months to 9 years (median = 51 months) after a first episode of VL. The clinical and biologic follow-up protocol included routine Leishmania detection using peripheral blood and a previously validated PCR method. Quantitative and qualitative variables were statistically analyzed. Results: Sixteen patients relapsed, for a total of 38 relapses. CD4 counts <100 cells/mu L and absence of highly active antiretroviral therapy at primary diagnosis and CD4 counts <100 cells/mu L during follow-up were the major predictive factors for relapse. No relapse occurred when CD4 counts were >200 cells/mu L. The Leishmania PCR assay was positive in all clinical relapses, and its negative predictive value was 100%. Conclusions: The PCR assay used here proved extremely useful for routine follow-up of VL in patients who had AIDS. Considering CD4 cell counts and Leishmania PCR assays, these results allow defining proposals for discontinuing secondary prophylaxis, and thus optimizing the clinical care of VL in these patients.
引用
收藏
页码:13 / 19
页数:7
相关论文
共 39 条
[1]   Leishmania and human immunodeficiency virus coinfection: The first 10 years [J].
Alvar, J ;
Canavate, C ;
GutierrezSolar, B ;
Jimenez, M ;
Laguna, F ;
LopezVelez, R ;
Molina, R ;
Moreno, J .
CLINICAL MICROBIOLOGY REVIEWS, 1997, 10 (02) :298-+
[2]   Clinical use of polymerase chain reaction performed on peripheral blood and bone marrow samples for the diagnosis and monitoring of visceral leishmaniasis in HIV-infected and HIV-uninfected patients: A single-center, 8-year experience in Italy and review of the literature [J].
Antinori, Spinello ;
Calattini, Sara ;
Longhi, Erika ;
Bestetti, Giovanna ;
Piolini, Roberta ;
Magni, Carlo ;
Orlando, Giovanna ;
Gramiccia, Marina ;
Acquaviva, Veronica ;
Foschi, Antonella ;
Corvasce, Stefano ;
Colomba, Claudia ;
Titone, Lucina ;
Parravicini, Carlo ;
Cascio, Antonio ;
Corbellino, Mario .
CLINICAL INFECTIOUS DISEASES, 2007, 44 (12) :1602-1610
[3]   Prevention of opportunistic infections in adult and adolescent patients with HIV infection.: GESIDA/National AIDS Plan guidelines, 2003 [J].
Berenguer, J ;
Laguna, F ;
López-Aldeguer, J ;
Moreno, S ;
Arribas, JR ;
Arrizabalaga, J ;
Baraia, J ;
Casado, JL ;
Cosín, J ;
Polo, R ;
González-García, J ;
Iribarren, JA ;
Kindelán, JM ;
De Quirós, JCLB ;
López-Vélez, R ;
Lorenzo, JF ;
Lozano, F ;
Mallolas, J ;
Miró, JM ;
Pulido, F ;
Ribera, E .
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2004, 22 (03) :160-176
[4]   Discontinuation of secondary anti-Leishmania prophylaxis in HIV-infected patients who have responded to highly active antiretroviral therapy [J].
Berenguer, J ;
Cosín, J ;
Miralles, P ;
López, JC ;
Padilla, B .
AIDS, 2000, 14 (18) :2946-2948
[5]   HIV viral load and response to antileishmanial chemotherapy in co-infected patients [J].
Berhe, N ;
Wolday, D ;
Hailu, A ;
Abraham, Y ;
Ali, A ;
Gebre-Michael, T ;
Desjeux, P ;
Sönnerborg, A ;
Akuffo, H ;
Britton, S .
AIDS, 1999, 13 (14) :1921-1925
[6]   Real-time PCR assay for clinical management of human immunodeficiency virus-infected patients with visceral leishmaniasis [J].
Bossolasco, S ;
Gaiera, G ;
Olchini, D ;
Gulletta, M ;
Martello, L ;
Bestetti, A ;
Bossi, L ;
Germagnoli, L ;
Lazzarin, A ;
Uberti-Foppa, C ;
Cinque, P .
JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (11) :5080-5084
[7]   Relapsing visceral leishmaniasis in HIV-infected patients undergoing successful protease inhibitor therapy [J].
Casado, JL ;
Lopez-Velez, R ;
Pintado, V ;
Quereda, C ;
Antela, A ;
Moreno, S .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2001, 20 (03) :202-205
[8]  
*CDCP, 1993, MMWR-MORBID MORTAL W, V41, P1
[9]  
Cruz I, 2002, Trans R Soc Trop Med Hyg, V96 Suppl 1, pS185
[10]   Incidence of and risk factors for symptomatic visceral leishmaniasis among human immunodeficiency virus type 1-infected patients from Spain in the era of highly active antiretroviral therapy [J].
de la Rosa, R ;
Pineda, JA ;
Delgado, J ;
Macías, J ;
Morillas, F ;
Mira, JA ;
Sánchez-Quijano, A ;
Leal, M ;
Lissen, E .
JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (03) :762-767